Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Equillium Q3 EPS $(0.35) Down From $(0.31) YoY

Equillium (NASDAQ:EQ) reported quarterly losses of $(0.35) per share. This is a 12.9 percent decrease over losses of $(0.31) per share from the same period last year.
byBenzinga Newsdesk
November 10, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0

Equillium (NASDAQ:EQ) reported quarterly losses of $(0.35) per share. This is a 12.9 percent decrease over losses of $(0.31) per share from the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

ALX Oncology Announced Initial Data from ASPEN-02, the Ongoing Phase 1 / 2 Study of Evorpacept in Combination with Azacitidine at ASH 2021; Said Complete Remissions With Cytogenetic Responses, Hematologic Improvement, and Transfusion Independence Were…

By Charles Gross
Today, 10:46 AM
ALX Oncology Holdings Inc., ("ALX Oncology") (NASDAQ: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced the presentation of initial clinical data from its ongoing trial evaluating evorpacept in combination with azacitidine for the treatment of patients wi

ALXO